Ignite Creation Date:
2024-05-05 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00147953
Status:
COMPLETED
Last Update Posted:
2010-01-27
First Post:
2005-09-02
Brief Title:
Study to Evaluate the Efficacy of Rituximab in Combination With Low-dose Radiotherapy in Patients With Relapsed Non-Hodgkins Lymphoma
Sponsor:
University of Cologne
Organization:
University of Cologne
Study Overview
Official Title:
A Phase II Study of Rituximab Plus Low-Dose Radiotherapy in Patients With Relapsed Non-Hodgkins Lymphoma
Status:
COMPLETED
Status Verified Date:
2010-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study aims to assess the short term efficacy of a combination of rituximab and low-dose radiotherapy in patients with non-Hodgkins lymphoma
Detailed Description:
Rituximab and low-dose total-nodal irradiation both have shown promising activity in patients with NHL Moreover the radiolabelled antibody Zevalin has been approved for the treatment of relapsed NHL The patients in this study have a poor prognosis The treatment strategy aims to control the disease and to ameliorate disease related symptoms with minimal toxicity Both rituximab and low-dose radiotherapy are associated with minor toxicity if applied alone
The primary objective of the study is therefore to assess the short term efficacy of a combination of rituximab and low-dose radiotherapy in patients with non-Hodgkins lymphoma
The primary objective of the study is therefore to assess the short term efficacy of a combination of rituximab and low-dose radiotherapy in patients with non-Hodgkins lymphoma
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None